rLj-RGD3全RGD缺失基因重组突变体—rLj-112分子克隆及其广谱抑真菌活性

Lj-112是日本七鳃鳗RGD毒素蛋白野生型Lj-RGD3的RGD全缺失基因突变体,其一级结构具有富组氨酸的特点.富组氨酸糖蛋白具有抑菌功能.为了研究Lj-112是否具有抑菌作用,使用基因合成和原核表达的方法,获得了纯化重组蛋白r Lj-112,将其对不同菌种进行抑菌试验.结果表明,以野生型r Lj-RGD3、RGD模体与组氨酸全缺失突变体r Lj-26为对照,r Lj-112有较广谱的抑菌活性,其中对白念球菌的最低抑菌浓度(MIC)为7μmol/L,对稻瘟病菌的MIC值为7.5μmol/L,对毛癣菌和禾谷病菌的MIC值分别为11.9μmol/L和29.9μmol/L.可见,r Lj-112能作为抗真菌药物候选,为提高农作物的生产质量和减轻人类感染疾病的用药压力奠定了基础.     

rLj-RGD3全RGD缺失基因重组突变体——rLj-112的分子克隆及其广谱抑真菌活性

Lj-112是日本七鳃鳗RGD毒素蛋白野生型Lj-RGD3的RGD全缺失基因突变体,其一级结构具有富组氨酸的特点．富组氨酸糖蛋白具有抑菌功能．为了研究Lj-112是否具有抑菌作用,使用基因合成和原核表达的方法,获得了纯化重组蛋白rLj-112,将其对不同菌种进行抑菌试验.结果表明,以野生型rLj-RGD3、RGD模体与组氨酸全缺失突变体rLj-26为对照,rLj-112有较广谱的抑菌活性,其中对白念球菌的最低抑菌浓度（MIC）为7 μmol/L,对稻瘟病菌的MIC值为7.5 μmol/L,对毛癣菌和禾谷病菌的MIC值分别为11.9 μmol/L和29.9 μmol/L．可见,rLj-112能作为抗真菌药物候选,为提高农作物的生产质量和减轻人类感染疾病的用药压力奠定了基础．     

日本七鳃鳗RGD毒素肽Lj-RGD2的克隆、表达及其抗血管新生活性

日本七鳃鳗口腔腺分泌蛋白Lj-RGD2毒素肽分子质量为8 kD,是含有2个RGD（Arg-Gly-Asp）模体序列的多肽.为了探讨其是否具有RGD毒素蛋白的功能,对其基因进行了克隆和表达,并对其重组蛋白进行了抗血管新生活性研究.从日本七鳃鳗口腔腺中提取mRNA,以自行设计的引物进行RT-PCR扩增,以获得Lj-RGD2基因;将获取的目的基因与pET23b载体连接,经转化、克隆、阳性转化子的筛选鉴定;将含组氨酸标签的pET23b-Lj-RGD2转化BL21菌中诱导表达;经亲和层析纯化,获得可溶性重组rLj-RGD2蛋白,并对重组rLj-RGD2蛋白的抗血管新生功能进行了研究.结果显示,rLj-RGD2蛋白的IC50为1.77μmol/L,并以剂量依赖方式抑制人脐静脉内皮细胞ECV304的增殖;rLj-RGD2蛋白还能抑制ECV304细胞对人工基质膜Matrigel的黏附、以BFGF（basic fibroblast growth factor）为趋化剂的迁移及侵袭.鸡胚绒毛尿囊膜CAM（chick chorioallantoic membrane）血管新生实验结果表明,rLj-RGD2蛋白能以剂量依赖方式抑制BFGF诱导的CAM血管新生.由此可见,rLj RGD2蛋白具有RGD毒素肽的活性特征,其有望成为一种抗血管新生基因工程新药. 关键词日本七鳃鳗; RGD毒素蛋白; 细胞黏附; 迁移及侵袭; 血管新生     

日本七鳃鳗富含半胱氨酸RGD蛋白Lj-RGD1抑制血小板聚集及抗血管新生功能

Lj-RGD1来源于日本七鳃鳗口腔腺,富含半胱氨酸并具有RGD(Arg-Gly-Asp)模体.为了验证Lj-RGD1是否具有抑制血小板聚集、抗血管新生等去整合素样典型功能,本文对七鳃鳗Lj-RGD1进行了克隆表达及活性测定.提取七鳃鳗口腔腺中总RNA进行RT-PCR扩增,获得Lj-RGD1的420 bp cDNA.对其进行克隆、表达及组氨酸亲和层析纯化后,获得分子量为169 kD的可溶性蛋白rLj-RGD1.活性测定结果显示,rLj-RGD1呈剂量依赖方式抑制ADP诱导的兔血小板聚集,IC50为123 μmol/L;血管新生抑制实验结果表明,rLj-RGD1能够诱导ECV304细胞凋亡,抑制ECV304细胞增殖和管状物形成,并呈剂量依赖性方式抑制鸡胚胎绒毛尿囊膜（chorioallantoic membrane,CAM）血管新生.由此可见,Lj-RGD1具有去整合素样生物活性,在血栓或血管异常新生类疾病治疗中具有应用前景.     

以整合素αvβ3为靶点的RGD配体在抗肿瘤血管新生中的应用

整合素αvβ3是一种能特异性识别RGD序列的膜受体蛋白,其与含RGD（Arg-Gly-Asp）模体的蛋白质结合的特异性在肿瘤细胞的粘附、迁移、浸润及肿瘤血管新生中起重要作用.由于整合素αvβ3在多种肿瘤细胞表面高表达而在正常细胞中低表达或不表达,因此其成为肿瘤治疗的理想靶点.肿瘤新生血管为肿瘤的生长提供营养,因此近年来抑制肿瘤血管新生也成为肿瘤治疗的重要途径.有研究显示,几种RGD毒素蛋白不但以整合素αvβ3为靶点靶向结合到肿瘤部位从而具有直接抗肿瘤细胞增殖、黏附、迁移及浸润功能,而且它们还具有抗肿瘤血管新生的作用,因此RGD毒素蛋白可从上述两方面抑制肿瘤生长与转移.本文就整合素αvβ3为靶向的RGD配体结构特点及其在肿瘤治疗中的靶向治疗和抗血管新生应用及前景加以综述.     

重组七鳃鳗富含半胱氨酸RGD蛋白rLj-RGD1对人肝癌HepG2细胞的抑制作用

rLj-RGD1为源于日本七鳃鳗口腔腺的基因重组蛋白,其富含半胱氨酸并具有一个RGD(Arg-Gly-Asp)模体.前期工作表明,rLj-RGD1具有抑制血小板聚集及血管新生的RGD毒素蛋白典型功能.为了研究rLj RGD1是否具有RGD毒素蛋白的另一典型抗肿瘤功能,以人肝癌HepG2细胞为模型,对rLj RGD1进行了活性研究.MTT法结果显示,rLj-RGD1呈剂量依赖方式抑制HepG2细胞的增殖,其半抑制浓度(IC50)为36 μmol/L;细胞迁移与浸润实验结果显示,rLj-RGD1能以剂量依赖方式抑制HepG2细胞碱性成纤维生长因子（bFGF）诱导的迁移与浸润.Hoechst染色和DNA Ladder等细胞凋亡实验表明,rLj-RGD1能够以剂量依赖方式诱导HepG2细胞发生凋亡.细胞黏附实验表明,rLj-RGD1以剂量依赖方式抑制HepG2细胞与玻连蛋白(vitronectin, VN)的黏附.上述结果表明,rLj-RGD1具有抑制人肝癌HepG2细胞增殖、迁移和浸润的功能,并可诱导其发生失巢凋亡. 本研究结果提示,rLj-RGD1具有典型的RGD毒素蛋白抗肿瘤功能,其未来具有成为抗肿瘤药物的潜力.     

富组氨酸糖蛋白(HRG)的结构与功能

富组氨酸糖蛋白(HRG)为一种多结构域血浆糖蛋白,可与多种配体结合而行使多种功能.HRG配体包括锌离子、肝素和硫酸肝素、纤溶酶原、纤溶酶、纤维蛋白原、凝血酶敏感素、原肌球蛋白、IgG、FcγR及补体.在锌离子存在或在低pH的环境中(如组织损伤或肿瘤生长),HRG的富含组氨酸结构域与配体的结合能力加强.HRG的多结构域特点及其与多种配体结合的性质表明,其可以作为细胞外衔接蛋白衔接细胞表面的不同配体.除了细胞表面分子,HRG还可以结合IgG,从而阻止可溶性免疫复合物的产生.HRG与大多数细胞发生结合的功能是在锌离子存在或低pH环境下,通过与细胞表面硫酸肝素蛋白聚糖相互作用实现的.HRG还具有加强凋亡细胞、坏死的吞噬细胞和免疫复合物的清除、抗血管新生、细胞的粘附和迁移、纤维蛋白溶解作用、血凝固、补体激活等生理活动调节等功能.本文针对HRG的分子结构与功能及其在临床上的研究进展进行概述.     

野生型rLj-RGD3基因重组突变体rLj-112分子克隆及对HeLa细胞活性影响

为研究突变体rLj-112蛋白的抗肿瘤活性,人工合成七鳃鳗野生型rLj-RGD3蛋白和突变型rLj-112蛋白,通过比较两种蛋白质的抗增殖、迁移和促凋亡的活性,确定突变体rLj-112蛋白的生物学意义及地位。采用MTT方法检测不同浓度的rLj-112蛋白对HeLa细胞增殖的抑制作用。结果表明,rLj-112蛋白能显著抑制HeLa细胞的增殖,且IC50为4.3 μmol/L。使用Transwell细胞培养板对bFGF诱导的HeLa细胞迁移实验表明,rLj-112蛋白能抑制HeLa细胞的迁移。rLj-112蛋白作用后,HeLa细胞经Hoechst33258和AnnexinV-FITC染色结果显示,细胞均凋亡。流式细胞仪进一步证明,rLj-112蛋白能诱导HeLa细胞发生凋亡,且呈剂量依赖性。由此可见,与野生型rLj-RGD3蛋白比较,突变型rLj-112蛋白有较高的细胞毒性作用,具有抗肿瘤的功能,有望应用于抗肿瘤基因工程药物的开发,具有重要的生物学意义。     

重组蛋白rLj-112对人非小细胞肺癌A549细胞增殖、迁移和凋亡的影响及其机制研究

该文研究了重组蛋白r Lj-112对人非小细胞肺癌A549细胞增殖、迁移和凋亡的影响及其作用机制。采用MTT(四甲基偶氮唑蓝)法检测r Lj-112对人非小细胞肺癌A549细胞增殖的影响,采用Transwell方法检测r Lj-112对A549细胞迁移和侵袭的影响,Hoechst和吉姆萨染色的方法检测r Lj-112对A549细胞凋亡的影响;采用Western blot法检测r Lj-112对A549细胞信号通路相关蛋白质水平的影响。结果表明,r Lj-112能够抑制A549细胞的增殖,半抑制浓度IC50值为1.64μmol/L;r Lj-112能抑制A549细胞的迁移和侵袭并呈剂量依赖性;r Lj-112能诱导A549细胞的凋亡;r Lj-112处理过的细胞cleaved-caspase3蛋白质和cleaved-PARP蛋白质水平升高,证明r Lj-112通过caspase3/PARP途径执行对A549细胞的凋亡的诱导,p-AKT、p-PI3K和p-Erk1/2的水平下降,提示r Lj-112的作用方式与PI3K/AKT相关信号通路有关。     

人凋亡相关基因TFAR19缺失突变体的原核表达、产物纯化及鉴定

构建TF 1细胞凋亡相关基因 19(TF 1cellapoptosisrelatedgene 19,TFAR19)缺失突变体的原核表达载体 ,获取缺失突变体蛋白 ,用于TFAR19促凋亡分子机理的研究 .从真核表达载体pcDI TFAR19扩增出野生型TFAR19和 4个缺失突变体 ,重组到原核表达载体pGEX 4T 2 .经亲和层析方法对缺失体蛋白进行纯化后 ,再利用凝胶过滤的方法进一步纯化 .利用抗GST和抗TFAR19的单克隆抗体对蛋白进行免疫学鉴定 .用白血病细胞株HL 6 0检测蛋白活性 .成功地克隆并重组了野生型TFAR19及缺失突变体 pGEX 4T 2表达载体 ,对融合蛋白的表达条件进行了优化 .SDS PAGE结果显示 ,各个缺失突变体融合蛋白均有较高水平的表达 .免疫学检测证实获得了正确的表达产物 .活性检测证实 ,野生型TFAR19和缺失突变体 4可以明显促进去血清诱导的HL 6 0细胞凋亡 ,第 6外显子可能是一个与TFAR19促凋亡活性密切相关的功能结构域     

重组七鳃鳗细胞毒素蛋白rLj-RGD3表达及对Hela细胞活性的影响

为研究重组七鳃鳗细胞毒素蛋白rLj-RGD3的抗肿瘤活性,确定其生物学地位及意义,本研究提取成体七鳃鳗(Lampetra japonica)口腔腺组织总RNA,经RT-PCR获得cDNA序列长度为357bp的目的基因片段,将其克隆于pET23b载体,获得带有组氨酸标签的分子量为15kD的基因重组蛋白rLj-RGD3的高效可溶性表达,通过组氨酸亲和层析纯化蛋白。采用MTT法检测不同浓度rLj-RGD3对bFGF诱导下的Hela细胞增殖的抑制作用,结果表明rLj-RGD3能显著抑制Hela细胞的增殖,IC50为2.6μmol/L。rLj-RGD3作用后的Hela细胞经Hoechst染色及DNAladder检测结果显示,细胞均发生凋亡。rLj-RGD3对Hela细胞黏附玻连蛋白(VN)作用的实验结果为有效抑制。采用Transwell细胞培养板对bFGF诱导下的Hela细胞迁移实验表明,rLj-RGD3能够抑制Hela细胞的迁移,且抑制率达60%。采用人工基质膜基质Matrigel及Transwell模仿体内环境研究rLj-RGD3对Hela细胞浸润行为实验显示,以bFGF为趋化剂的Hela细胞穿透Matrigel的...     

A novel RGD-toxin protein,Lj-RGD3, from the buccal gland secretion of Lampetra japonica impacts diverse biological activities

RGD (Arg-Gly-Asp) motif toxin proteins from snake venoms, saliva glands secretion of leech or tick have typical characteristics of inhibiting platelet aggregation, angiogenesis, and tumor growth. Here we report cloning and characterization of a novel RGD-toxin protein from the buccal gland of Lampetra japonica. In an attempt to study the activities of anticoagulant in the buccal gland secretion of L. japonica, we established buccal gland cDNA library and identified a gene encoding a predicted protein of 118 amino acids with 3 RGD motifs. The predicted protein was named Lj-RGD3. We generated the cDNA of Lj-RGD3 and obtained the recombinant protein rLj-RGD3. The polyclonal antibodies against rLj-RGD3 recognized the native Lj-RGD3 protein in buccal gland secretion in Western blot analyses. The biological function studies reveal that rLj-RGD3 inhibited human platelet aggregation in a dose-dependent manner with IC₅₀ value at 5.277 μM. In addition, rLj-RGD3 repressed bFGF-induced angiogenesis in the chick chorioallantoic membrane model. rLj-RGD3 also inhibited the adhesion of ECV304 cells to vitronectin. Furthermore, rLj-RGD3 induced apoptosis and significantly inhibited proliferation, migration, and invasion evoked by bFGF in ECV304 cells. Taken together, these results suggested that rLj-RGD3 is a novel RGD-toxin protein possessing typical functions of the RGD-toxin protein.     

Entamoeba histolytica : a novel cysteine protease and an adhesin form the 112 kDa surface protein

Here, we present evidence that a cysteine protease (EhCP112) and a protein with an adherence domain (EhADH112) form the Entamoeba histolytica 112 kDa adhesin. Immunoelectron microscopy and immunofluorescence assays using monoclonal antibodies (mAbAdh) revealed that, during phagocytosis, the adhesin is translocated from the plasma membrane to phagocytic vacuoles. mAbAdh inhibited 54% adherence, 41% phagocytosis, and 35% and 62% destruction of MDCK cell monolayers by live trophozoites and their extracts respectively. We cloned a 3587 bp DNA fragment (Eh112 ) with two open reading frames (ORFs) separated by a 188 bp non-coding region. The ORF at the 5' end (Ehcp112 ) encodes a protein with a cysteine protease active site, a transmembranal segment and an RGD motif. The second ORF (Ehadh112 ) encodes a protein recognized by mAbAdh with three putative transmembranal segments and four glycosylation sites. Northern blot, primer extension and Southern blot experiments revealed that Ehcp112 and Ehadh112 are two adjacent genes in DNA. Ehcp112 and Ehadh112 genes were expressed in bacteria. The recombinant peptides presented protease activity and inhibited adherence and phagocytosis, respectively, and both were recognized by mAbAdh. The EhCP112 and EhADH112 peptides could be joined by covalent or strong electrostatic forces, which are not broken during phagocytosis.     

Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells

The present study addresses the capacity of heregulin (HRG), a ligand of type I receptor tyrosine kinases, to transactivate the progesterone receptor (PR). For this purpose, we studied, on the one hand, an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in female BALB/c mice and, on the other hand, the human breast cancer cell line T47D. HRG was able to exquisitely regulate biochemical attributes of PR in a way that mimicked PR activation by progestins. Thus, HRG treatment of primary cultures of epithelial cells of the progestin-dependent C4HD murine mammary tumor line and of T47D cells induced a decrease of protein levels of PRA and -B isoforms and the downregulation of progesterone-binding sites. HRG also promoted a significant increase in the percentage of PR localized in the nucleus in both cell types. DNA mobility shift assay revealed that HRG was able to induce PR binding to a progesterone response element (PRE) in C4HD and T47D cells. Transient transfections of C4HD and T47D cells with a plasmid containing a PRE upstream of a chloramphenicol acetyltransferase (CAT) gene demonstrated that HRG promoted a significant increase in CAT activity. In order to assess the molecular mechanisms underlying PR transactivation by HRG, we blocked ErbB-2 expression in C4HD and T47D cells by using antisense oligodeoxynucleotides to ErbB-2 mRNA, which resulted in the abolishment of HRG's capacity to induce PR binding to a PRE, as well as CAT activity in the transient-transfection assays. Although the inhibition of HRG binding to ErbB-3 by an anti-ErbB-3 monoclonal antibody suppressed HRG-induced PR activation, the abolishment of HRG binding to ErbB-4 had no effect on HRG activation of PR. To investigate the role of mitogen-activated protein kinases (MAPKs), we used the selective MEK1/MAPK inhibitor PD98059. Blockage of MAPK activation resulted in complete abrogation of HRG's capacity to induce PR binding to a PRE, as well as CAT activity. Finally, we demonstrate here for the first time that HRG-activated MAPK can phosphorylate both human and mouse PR in vitro.     

Differential binding of histidine-rich glycoprotein (HRG) to human IgG subclasses and IgG molecules containing kappa and lambda light chains.

In previous studies we showed that the plasma protein histidine-rich glycoprotein (HRG) binds strongly to pooled human IgG. In the present work myeloma proteins consisting of different human IgG subclasses were examined for their ability to interact with human HRG. Using an IAsys optical biosensor we found initially that IgG subclasses differ substantially in their affinity of interaction with HRG. However, the most striking finding was the observation that the kinetics of the HRG interaction was dramatically affected by whether the IgG subclasses contained the kappa or lambda light (L)-chains. Thus, the on-rate for the binding of HRG to the kappa L-chain containing IgG1 and IgG2 (IgG1kappa and IgG2kappa) was approximately 4- and approximately 10-fold faster than that for the binding of HRG to lambda L-chain containing IgG1 and IgG2 (IgG1lambda and IgG2lambda), respectively, with the dissociation constants (K(d)) in the range 3-5 nM and 112-189 nM for the kappa and lambda isoforms, respectively. In contrast, the on-rate for the binding of HRG to IgG3kappa and IgG4kappa was found to be 9- and 20-fold slower than that for the binding of HRG to IgG3lambda and IgG4lambda, respectively, with the K(d) in the range 147-268 nM and 96-109 nM for the kappa and lambda isoforms, respectively. The binding of HRG to immunoglobulins containing the kappa L-chain (particularly IgG1kappa) was generally potentiated in the presence of a physiological concentration (20 microM) of Zn(2+) (K(d) decreased to 0.60 +/- 0.01 for IgG1kappa), but Zn(2+) had no effect or slightly inhibited the binding of HRG to immobilized IgG subclasses possessing the lambda L-chain. Interestingly, HRG also bound differentially to Bence Jones (BJ) proteins containing kappa and lambda L-chains, with HRG having a 14-fold lower K(d) for BJkappa than for BJlambda when 20 microM Zn(2+) was present. HRG also bound to IgM (IgMkappa), but the affinity of this interaction (K(d) approximately 1.99 +/- 0.05 microM) was markedly lower than the interaction with IgG, and the affinity was actually decreased 4-fold in the presence of Zn(2+). The results demonstrate that both the heavy (H)- and L-chain type have a profound effect on the binding of HRG to different IgG subclasses and provide the first evidence of a functional difference between the kappa and lambda L-chains of immunoglobulins.     

Photoreceptor synaptic protein HRG4 (UNC119) interacts with ARL2 via a putative conserved domain

Human retinal gene 4 (HRG4) (UNC119) is a photoreceptor synaptic protein of unknown function, shown when mutated to cause retinal degeneration in a patient and in a confirmatory transgenic model. ADP-ribosylation factor-like protein 2 (ARL2) was identified as an interactor of HRG4 by the yeast two-hybrid strategy. The presence of ARL2 in the retina and co-localization with HRG4 was confirmed by Western blot and double immunofluorescence analysis, respectively. The interaction of ARL2 with HRG4 was further confirmed by co-immunoprecipitation and direct binding analysis. Phosphodiesterase delta (PDEdelta) is an ARL2-binding protein homologous to HRG4. Amino acid residues of PDEdelta involved in binding ARL2 and forming a hydrophobic pocket were shown to be highly conserved in HRG4, suggesting similarity in binding mechanism and function.     

Evidence that muscle cells do not express the histidine-rich glycoprotein associated with AMP deaminase but can internalise the plasma protein

Histidine-rich glycoprotein (HRG) is synthesized by liver and is present at relatively high concentration in the plasma of vertebrates. We have previously described the association of a HRG-like molecule to purified rabbit skeletal muscle AMP deaminase (AMPD). We also provided the first evidence for the presence of a HRG-like protein in human skeletal muscle where a positive correlation between HRG content and total determined AMPD activity has been shown. In the present paper we investigate the origin of skeletal muscle HRG. The screening of a human skeletal muscle cDNA expression library using an anti-HRG antibody failed to reveal any positive clone. The RT-PCR analysis, performed on human skeletal muscle RNA as well as on RNA from the rhabdomyosarcoma (RD) cell line, failed to show any mRNA specific for the plasma HRG or for the putative muscle variant. When the RD cells were incubated with human plasma HRG, a time-dependent increase of the HRG immunoreactivity was detected both at the plasma membrane level and intracellularly. The internalisation of HRG was inhibited by the addition of heparin. The above data strongly suggest that skeletal muscle cells do not synthesize the muscle variant of HRG but instead can actively internalise it from plasma.